1. Home
  2. LEA vs ACAD Comparison

LEA vs ACAD Comparison

Compare LEA & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEA
  • ACAD
  • Stock Information
  • Founded
  • LEA 1917
  • ACAD 1993
  • Country
  • LEA United States
  • ACAD United States
  • Employees
  • LEA N/A
  • ACAD N/A
  • Industry
  • LEA Auto Parts:O.E.M.
  • ACAD Biotechnology: Pharmaceutical Preparations
  • Sector
  • LEA Consumer Discretionary
  • ACAD Health Care
  • Exchange
  • LEA Nasdaq
  • ACAD Nasdaq
  • Market Cap
  • LEA 4.7B
  • ACAD 3.8B
  • IPO Year
  • LEA N/A
  • ACAD 2004
  • Fundamental
  • Price
  • LEA $103.65
  • ACAD $20.95
  • Analyst Decision
  • LEA Buy
  • ACAD Buy
  • Analyst Count
  • LEA 12
  • ACAD 19
  • Target Price
  • LEA $112.25
  • ACAD $27.89
  • AVG Volume (30 Days)
  • LEA 728.9K
  • ACAD 2.0M
  • Earning Date
  • LEA 07-24-2025
  • ACAD 08-05-2025
  • Dividend Yield
  • LEA 2.97%
  • ACAD N/A
  • EPS Growth
  • LEA N/A
  • ACAD N/A
  • EPS
  • LEA 8.59
  • ACAD 1.37
  • Revenue
  • LEA $22,871,700,000.00
  • ACAD $996,283,000.00
  • Revenue This Year
  • LEA N/A
  • ACAD $13.39
  • Revenue Next Year
  • LEA $3.36
  • ACAD $10.59
  • P/E Ratio
  • LEA $12.06
  • ACAD $15.31
  • Revenue Growth
  • LEA N/A
  • ACAD 22.42
  • 52 Week Low
  • LEA $73.85
  • ACAD $13.40
  • 52 Week High
  • LEA $126.85
  • ACAD $25.23
  • Technical
  • Relative Strength Index (RSI)
  • LEA 74.05
  • ACAD 44.08
  • Support Level
  • LEA $93.40
  • ACAD $21.16
  • Resistance Level
  • LEA $95.61
  • ACAD $23.09
  • Average True Range (ATR)
  • LEA 2.36
  • ACAD 0.79
  • MACD
  • LEA 1.20
  • ACAD -0.34
  • Stochastic Oscillator
  • LEA 91.30
  • ACAD 4.58

About LEA Lear Corporation

Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns most of its revenue from the seating segment.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: